Oseaspre Consultants Approves FY26 Audited Results, Recommends ₹87 Dividend Per Share

5 min read     Updated on 16 May 2026, 12:41 AM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Oseaspre Consultants held its board meeting on May 15, 2026, approving audited financial results for the quarter and full year ended March 31, 2026. The company reported a net loss after tax of ₹18.28 lakhs for FY26 against a net profit of ₹3.98 lakhs in FY25, with total income declining to ₹3.32 lakhs from ₹21.80 lakhs. Total comprehensive income for FY26 stood at ₹142.28 lakhs, supported by OCI of ₹160.56 lakhs from the sale of equity instruments. The board recommended a final dividend of ₹87 per equity share of ₹10 each, with the 44th AGM set for June 19, 2026, and a record date of June 12, 2026.

powered bylight_fuzz_icon
40042789

*this image is generated using AI for illustrative purposes only.

Oseaspre Consultants held its Board of Directors meeting on May 15, 2026, wherein the board considered and approved the audited financial results for the quarter and financial year ended March 31, 2026, in compliance with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting commenced at 3:30 P.M. (IST) and concluded at 4:25 P.M. (IST). The intimation was signed by Ganesh S. Pardeshi, Company Secretary (Membership No.: A29080), and submitted to BSE Limited.

Board Meeting Outcome

The board transacted the following key agenda items during the meeting:

Parameter: Details
Meeting Date: Friday, May 15, 2026
Regulatory Provision: Regulation 30 and 33, SEBI (LODR) Regulations, 2015
Audited Results: Quarter and financial year ended March 31, 2026
Statutory Auditor: M/s Manek & Associates, Chartered Accountants (Firm Reg. No. 0126679W)
Audit Opinion: Unmodified
Dividend Recommended: ₹87/- per equity share of ₹10/- each
AGM Date: Friday, June 19, 2026 (44th Annual General Meeting)
Record Date: Friday, June 12, 2026
Book Closure Period: Saturday, June 13, 2026 to Friday, June 19, 2026 (both days inclusive)

Financial Performance

The company reported a net loss after tax of ₹18.28 lakhs for the full financial year ended March 31, 2026, compared to a net profit of ₹3.98 lakhs in the previous year. For the quarter ended March 31, 2026, the net loss stood at ₹6.47 lakhs, against a net profit of ₹14.25 lakhs in the corresponding quarter of the previous year. Total income for the full year declined to ₹3.32 lakhs from ₹21.80 lakhs, as revenue from operations was nil for FY26 compared to ₹18.00 lakhs in FY25. The following table presents the key financial results:

Metric: Q4 FY26 Q3 FY26 Q4 FY25 FY26 FY25
Revenue from Operations (₹ Lakhs): - - 18.00 - 18.00
Other Income (₹ Lakhs): 1.39 0.95 0.55 3.32 3.80
Total Income (₹ Lakhs): 1.39 0.95 18.55 3.32 21.80
Total Expenses (₹ Lakhs): 6.67 4.78 4.30 20.41 17.82
Profit/(Loss) Before Tax (₹ Lakhs): (5.28) (3.83) 14.25 (17.09) 3.98
Net Profit/(Loss) After Tax (₹ Lakhs): (6.47) (3.83) 14.25 (18.28) 3.98
Other Comprehensive Income (₹ Lakhs): 160.56 - - 160.56 -
Total Comprehensive Income (₹ Lakhs): 154.09 (3.83) 14.25 142.28 3.98
Basic EPS (₹): (3.24) (1.92) 7.13 (9.14) 1.99
Diluted EPS (₹): (3.24) (1.92) 7.13 (9.14) 1.99

Other Comprehensive Income (OCI) for FY26 stood at ₹160.56 lakhs, primarily driven by a realization on sale of equity instruments amounting to ₹178.52 lakhs (net of tax of ₹17.50 lakhs), partially offset by an actuarial valuation loss of ₹0.61 lakhs (net of tax benefit of ₹0.15 lakhs). As a result, total comprehensive income for the full year was ₹142.28 lakhs.

Balance Sheet Highlights

The company's balance sheet as at March 31, 2026 reflected a significant improvement in cash and cash equivalents, which rose to ₹209.83 lakhs from ₹0.77 lakhs in the previous year, largely on account of proceeds from investing activities. Total assets stood at ₹217.26 lakhs as against ₹72.84 lakhs in the prior year. The following table summarises the key balance sheet figures:

Particulars: As at 31.03.2026 (₹ Lakhs) As at 31.03.2025 (₹ Lakhs)
Total Non-Current Assets: 3.00 0.86
Total Current Assets: 214.26 71.98
Total Assets: 217.26 72.84
Total Shareholders' Funds: 212.44 70.15
Total Non-Current Liabilities: 3.82 1.51
Total Current Liabilities: 1.00 2.69
Total Equity and Liabilities: 217.26 72.84
Equity Share Capital (₹ Lakhs): 20.00 20.00
Other Equity (₹ Lakhs): 192.44 50.15

Cash Flow Summary

For the financial year ended March 31, 2026, net cash used in operating activities was ₹21.92 lakhs, while net cash generated from investing activities amounted to ₹230.98 lakhs, primarily from the sale of investments measured at FVTOCI (₹178.52 lakhs) and proceeds from mutual funds. There were no financing activities during the year. As a result, net cash and cash equivalents increased by ₹209.06 lakhs during the year, closing at ₹209.83 lakhs.

Dividend and AGM Details

The board has recommended a final dividend of ₹87/- per equity share of ₹10/- each for the financial year ended March 31, 2026, subject to approval at the 44th Annual General Meeting scheduled for Friday, June 19, 2026. The dividend, if declared, will be paid subject to deduction or withholding of applicable taxes within the timelines prescribed under law. The Register of Members and Share Transfer Books will remain closed from Saturday, June 13, 2026 to Friday, June 19, 2026 (both days inclusive), with Friday, June 12, 2026 as the record date for the AGM and final dividend.

Regulatory Compliance and Audit

The audited financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 15, 2026. The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. M/s Manek & Associates, Chartered Accountants, issued an unmodified audit opinion on the annual audited financial results for FY26. The results were published in accordance with Regulation 33 of the SEBI (LODR) Regulations, 2015, and are also available on the company's website. The company has no reportable segments as per Ind AS 108, 'Operating Segment'.

Historical Stock Returns for Oseaspre Consultants

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%0.0%0.0%0.0%0.0%0.0%

With zero revenue from operations in FY26 and a net operating loss, what strategic plans does Oseaspre Consultants have to revive its core business and generate sustainable revenue in FY27?

Given that the ₹87/- per share dividend significantly exceeds the company's earnings and is funded by proceeds from asset liquidation, is this dividend policy sustainable, and what does it signal about the company's long-term capital allocation strategy?

Since the company's cash position surged to ₹209.83 lakhs primarily from selling equity investments, how does management plan to deploy this liquidity to generate future returns and avoid further operational losses?

Technojet Consultants Limited Divests 48,000 Equity Shares in INOR Medical Products

1 min read     Updated on 25 Feb 2026, 05:34 PM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Technojet Consultants Limited announced the complete divestment of its 48,000 equity shares in INOR Medical Products Limited to Nowrosjee Wadia and Sons Limited through a regulatory filing. The transaction was disclosed under SEBI LODR Regulation 30, with Company Secretary Bhumika Ojha signing the disclosure on 25th February, 2026.

powered bylight_fuzz_icon
33566485

*this image is generated using AI for illustrative purposes only.

Technojet Consultants Limited has announced the divestment of its equity stake in INOR Medical Products Limited through a regulatory filing dated 25th February, 2026. The transaction represents a strategic portfolio adjustment by the company as it exits its investment in the unlisted medical products manufacturer.

Transaction Details

The divestment involves the complete sale of Technojet Consultants Limited's holding in INOR Medical Products Limited. The company has disclosed the transaction details in compliance with regulatory requirements.

Parameter: Details
Shares Sold: 48,000 Equity Shares
Target Company: INOR Medical Products Limited (Unlisted)
Buyer: Nowrosjee Wadia and Sons Limited
Disclosure Date: 25th February, 2026
Filing Time: 16:41:04 +05'30'

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to disclose material events and information that could impact investor decisions.

The disclosure was signed by Bhumika Ojha, Company Secretary (Membership No.: A79488), ensuring proper corporate governance protocols were followed. The digital signature was applied on 25th February, 2026, at 16:41:04 +05'30', confirming the authenticity of the regulatory filing.

Corporate Background

Technojet Consultants Limited operates under CIN L74210MH1982PLC027651 and maintains its listing on BSE Limited with scrip code 509917. The company's decision to divest from INOR Medical Products Limited reflects its ongoing portfolio management strategy, though specific financial details of the transaction were not disclosed in the regulatory filing.

Historical Stock Returns for Oseaspre Consultants

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%0.0%0.0%0.0%0.0%0.0%

More News on Oseaspre Consultants

1 Year Returns:0.00%